Market research
RDHL Redhill Biopharma Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- 0.0
- Analyst target
- 19000
- Dividend yield
- Not available
- Beta
- 4.9
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US7574683014
- Market cap
- 4M
- P/E ratio
- 0.0
- Analyst target
- 19000
- Dividend yield
- Not available
- Beta
- 4.9
About
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RDHL discussion.
5 years, 4 months ago
RedHill Biopharma Ltd is currently in a long term downtrend where the price is trading 21.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.0.
RedHill Biopharma Ltd's total revenue rose by 1249.7% to $21M since the same quarter in the previous year.
Its net income has dropped by 108.1% to $-24M since the same quarter in the previous year.
Finally, its free cash flow grew by 8.5% to $-13M since the same quarter in the previous year.
Based on the above factors, RedHill Biopharma Ltd gets an overall score of 3/5.